{"id":7454,"date":"2023-10-26T13:28:18","date_gmt":"2023-10-26T05:28:18","guid":{"rendered":"https:\/\/be.tworg.app\/%e5%9f%ba%e5%9b%a0%e5%af%a6%e7%8f%be%e7%99%8c%e7%97%87%e6%b2%bb%e7%99%82%e3%80%8c%e7%b2%be%e6%ba%96%e5%8c%96%e3%80%8d%ef%bc%81\/"},"modified":"2025-11-02T19:44:24","modified_gmt":"2025-11-02T11:44:24","slug":"%e5%9f%ba%e5%9b%a0%e5%af%a6%e7%8f%be%e7%99%8c%e7%97%87%e6%b2%bb%e7%99%82%e3%80%8c%e7%b2%be%e6%ba%96%e5%8c%96%e3%80%8d%ef%bc%81","status":"publish","type":"post","link":"https:\/\/behealthventures.com\/zh-hant\/%e5%9f%ba%e5%9b%a0%e5%af%a6%e7%8f%be%e7%99%8c%e7%97%87%e6%b2%bb%e7%99%82%e3%80%8c%e7%b2%be%e6%ba%96%e5%8c%96%e3%80%8d%ef%bc%81\/","title":{"rendered":"\u57fa\u56e0\u5be6\u73fe\u764c\u75c7\u6cbb\u7642\u300c\u7cbe\u6e96\u5316\u300d\uff01"},"content":{"rendered":"
\n

\u4e0a\u4e00\u7bc7\u6211\u5011\u7c21\u55ae\u8aaa\u660e\u4e86\u57fa\u56e0\u8207\u764c\u75c7\u53ca\u5169\u8005\u9593\u7684\u95dc\u806f\u6027\uff0c\u9019\u4e00\u7bc7\u6211\u5011\u4f86\u804a\u804a\u904e\u5f80\u6709\u54ea\u4e9b\u764c\u75c7\u6cbb\u7642\u65b9\u5f0f\uff0c\u4ee5\u53ca\u76ee\u524d\u57fa\u56e0\u6578\u64da\u662f\u5982\u4f55\u61c9\u7528\u65bc\u764c\u75c7\u6cbb\u7642\uff0c\u4e26\u9010\u6b65\u5be6\u73fe\u300c\u7cbe\u6e96\u91ab\u7642\u300d\u7684\u6982\u5ff5\u3002<\/strong><\/span><\/h4>\n<\/div>\n
\n

\u6bd4\u7ffc\u751f\u91ab\u5275\u6295 \u91ab\u7642\u4e8b\u52d9\u7d93\u7406 \u9673\u9577\u6ea2<\/span><\/p>\n<\/div>\n

\n
\n
\n
\n
\n
\"ree\"<\/div>\n<\/div>\n<\/figure>\n<\/div>\n<\/div>\n<\/div>\n
\n

\u73fe\u884c\u7684\u764c\u75c7\u6cbb\u7642\u65b9\u5f0f<\/strong><\/span><\/h2>\n<\/div>\n
\n

\u764c\u75c7\u6cbb\u7642\u7d93\u5e38\u9700\u6839\u64da\u60a3\u8005\u7684\u75be\u75c5\u72c0\u614b\uff0c\u5982\u764c\u75c7\u985e\u578b\u3001\u671f\u5225\u3001\u5fa9\u767c\u8207\u5426\uff0c\u4ee5\u53ca\u816b\u7624\u672c\u8eab\u7684\u7279\u5fb5\u7b49\uff0c\u800c\u64ec\u5b9a\u4e0d\u540c\u7684\u6cbb\u7642\u8a08\u756b\u3002\u4e14\u53c8\u53ef\u4f9d\u64da\u6cbb\u7642\u65b9\u5f0f\u7684\u7279\u6027\uff0c\u5927\u6982\u5340\u5206\u70ba\u5c0d\u5168\u8eab\u90fd\u53ef\u80fd\u9020\u6210\u5f71\u97ff\u7684\u5168\u8eab\u6027\u6cbb\u7642\uff0c\u8207\u50c5\u91dd\u5c0d\u7279\u5b9a\u8eab\u9ad4\u90e8\u4f4d\u6216\u7279\u5b9a\u816b\u7624\u7684\u5340\u57df\u6027\u6cbb\u7642\u3002\u7531\u65bc\u764c\u75c7\u7684\u6cbb\u7642\u65b9\u5f0f\u65e5\u65b0\u6708\u7570\uff0c\u56e0\u6b64\u672c\u7ae0\u7bc0\u5c07\u50c5\u7c21\u4ecb\u76ee\u524d\u5e38\u898b\u7684\u4e03\u5927\u6cbb\u7642\u65b9\u5f0f\uff0c\u5305\u62ec\u624b\u8853\u6cbb\u7642\u3001\u5316\u5b78\u6cbb\u7642 (Chemotherapy)\u3001\u653e\u5c04\u6cbb\u7642 (Radiotherapy)\u3001\u8cc0\u723e\u8499\u6cbb\u7642 (Hormone therapy)\u3001\u5e79\u7d30\u80de\u79fb\u690d (Hematopoietic stem cell transplantation, HSCT)\u3001\u6a19\u9776\u6cbb\u7642 (Targeted therapy) \u8207\u514d\u75ab\u6cbb\u7642 (Immunotherapy)\u3002<\/span><\/p>\n<\/div>\n

\n

\u2022 \u624b\u8853\u6cbb\u7642:<\/strong><\/span><\/p>\n<\/div>\n

\n

\u900f\u904e\u5916\u79d1\u624b\u8853\u7684\u65b9\u5f0f\uff0c\u79fb\u9664\u7279\u5b9a\u90e8\u4f4d\u7684\u816b\u7624\u7d44\u7e54\u3002\u5927\u591a\u6578\u7684\u764c\u75c7\u60a3\u8005\u4e00\u958b\u59cb\u90fd\u6703\u7d93\u6b77\u624b\u8853\u6cbb\u7642\uff0c\u723e\u5f8c\u518d\u642d\u914d\u5176\u4ed6\u6cbb\u7642\u65b9\u5f0f\uff0c\u4ee5\u5b8c\u6210\u968e\u6bb5\u6027\u6cbb\u7642\u3002<\/span><\/p>\n<\/div>\n

\n

\u2022 \u5316\u5b78\u6cbb\u7642:<\/strong><\/span><\/p>\n<\/div>\n

\n

\u900f\u904e\u85e5\u7269\u6cbb\u7642\u7684\u65b9\u5f0f\u4f86\u6bba\u6b7b\u764c\u7d30\u80de\uff0c\u5982\u6291\u5236\u764c\u7d30\u80de\u751f\u9577\u3001\u963b\u65b7\u764c\u7d30\u80de\u5206\u88c2\u6216\u8feb\u4f7f\u764c\u7d30\u80de\u51cb\u4ea1\u7b49\u3002\u5316\u5b78\u6cbb\u7642\u85e5\u7269\u53ef\u96a8\u8457\u8840\u6db2\u5faa\u74b0\u5230\u9054\u5168\u8eab\uff0c\u4e14\u5176\u7121\u7279\u5b9a\u5c08\u4e00\u6027\uff0c\u5728\u64ca\u6bba\u764c\u7d30\u80de\u7684\u540c\u6642\uff0c\u4e5f\u6703\u5c0d\u6b63\u5e38\u7d30\u80de\u9020\u6210\u5f71\u97ff\uff0c\u5e38\u4f34\u96a8\u526f\u4f5c\u7528\u7684\u767c\u751f\uff0c\u5982\u6389\u9aee\u3001\u5641\u5fc3\u5614\u5410\u7b49\u3002<\/span><\/p>\n<\/div>\n

\n

\u2022 \u653e\u5c04\u6cbb\u7642:<\/strong><\/span><\/p>\n<\/div>\n

\n

\u900f\u904e\u9ad8\u5291\u91cf\u8f3b\u5c04\u4f86\u7834\u58de\u764c\u7d30\u80de\u7684DNA\uff0c\u9032\u800c\u6291\u5236\u764c\u7d30\u80de\u7684\u751f\u9577\u5206\u88c2\u800c\u6b7b\u4ea1\u3002\u653e\u5c04\u6cbb\u7642\u901a\u5e38\u9700\u7b49\u5f85\u764c\u7d30\u80deDNA\u7684\u640d\u50b7\u7d2f\u7a4d\u5230\u4e00\u5b9a\u7a0b\u5ea6\u5f8c\uff0c\u65b9\u53ef\u9020\u6210\u764c\u7d30\u80de\u6b7b\u4ea1\uff0c\u56e0\u6b64\u5e38\u9700\u5e7e\u5929\u81f3\u5e7e\u9031\u7684\u6642\u9593\u3002\u4e14\u5927\u591a\u70ba\u5340\u57df\u6027\u7167\u5c04\uff0c\u50c5\u91dd\u5c0d\u7279\u5b9a\u90e8\u4f4d\u8655\u7406\uff0c\u6700\u5c0f\u5316\u56e0\u6cbb\u7642\u53d7\u640d\u7684\u6b63\u5e38\u7d30\u80de\u3002<\/span><\/p>\n<\/div>\n

\n

\u2022 \u8cc0\u723e\u8499\u6cbb\u7642:<\/strong><\/span><\/p>\n<\/div>\n

\n

\u67d0\u4e9b\u764c\u75c7\u751f\u9577\u53ef\u80fd\u9700\u4ef0\u8cf4\u9ad4\u5167\u7279\u5b9a\u8cc0\u723e\u8499\uff0c\u5982\u4e73\u764c\u3001\u5375\u5de2\u764c\u8207\u524d\u5217\u817a\u764c\u7b49\uff0c\u6b64\u6642\u82e5\u4f7f\u7528\u6297\u8cc0\u723e\u8499\u85e5\u7269\uff0c\u963b\u65b7\u764c\u7d30\u80de\u8207\u8cc0\u723e\u8499\u7684\u7d50\u5408\uff0c\u4fbf\u6709\u6a5f\u6703\u6291\u5236\u764c\u7d30\u80de\u751f\u9577\u3002\u4f46\u4e26\u975e\u4e0a\u8ff0\u764c\u75c7\u60a3\u8005\u7686\u53ef\u63a1\u7528\u6b64\u7a2e\u6cbb\u7642\u65b9\u5f0f\uff0c\u9084\u9700\u8003\u91cf\u5176\u764c\u7d30\u80de\u7684\u8cc0\u723e\u8499\u53d7\u9ad4\u591a\u5be1\u3002<\/span><\/p>\n<\/div>\n

\n

\u2022 \u5e79\u7d30\u80de\u79fb\u690d:<\/strong><\/span><\/p>\n<\/div>\n

\n

\u9996\u5148\u4ee5\u9ad8\u5291\u91cf\u7684\u85e5\u7269\u8207\u8f3b\u5c04\u7b49\u65b9\u5f0f\uff0c\u5168\u8eab\u6027\u7684\u6bba\u6b7b\u764c\u7d30\u80de\uff0c\u4e26\u964d\u4f4e\u514d\u75ab\u7cfb\u7d71\u7684\u6d3b\u6027\uff0c\u518d\u900f\u904e\u6b63\u5e38\u5e79\u7d30\u80de\u7684\u79fb\u690d\uff0c\u4ee5\u91cd\u5efa\u9020\u8840\u8207\u514d\u75ab\u7cfb\u7d71\u3002\u6b64\u7a2e\u6cbb\u7642\u65b9\u5f0f\u901a\u5e38\u7528\u65bc\u8840\u6db2\u76f8\u95dc\u764c\u75c7\uff0c\u5982\u8840\u764c\u3001\u6dcb\u5df4\u764c\u8207\u591a\u767c\u6027\u9aa8\u9ad3\u7624\u7b49\u3002<\/span><\/p>\n<\/div>\n

\n

\u4e0a\u8ff0\u4e94\u7a2e\u6cbb\u7642\u7686\u662f\u900f\u904e\u9593\u63a5\u9776\u5411\u7684\u65b9\u5f0f\uff0c\u5373\u7121\u6cd5\u76f4\u63a5\u91dd\u5c0d\u5e36\u6709\u67d0\u7a2e\u7279\u6027\u7684\u764c\u7d30\u80de\uff0c\u800c\u63a5\u4e0b\u4f86\u5169\u7a2e\u6cbb\u7642\u65b9\u5f0f\u5247\u662f\u4ee5\u57fa\u56e0\u6578\u64da\u70ba\u4e3b\u8ef8\uff0c\u7279\u5b9a\u764c\u7d30\u80de\u70ba\u6a19\u7684\uff0c\u4ee5\u589e\u52a0\u6cbb\u7642\u6709\u6548\u6027\u8207\u6e1b\u5c11\u526f\u4f5c\u7528\u767c\u751f\u3002<\/span><\/p>\n<\/div>\n

\n

\u2022 \u6a19\u9776\u6cbb\u7642:<\/strong><\/span><\/p>\n<\/div>\n

\n

\u900f\u904e\u50c5\u91dd\u5c0d\u5e36\u6709\u7279\u5b9a\u300c\u57fa\u56e0\u8b8a\u7570\u300d\u7684\u764c\u7d30\u80de\u9032\u884c\u7279\u5b9a\u85e5\u7269\u7684\u6cbb\u7642\uff0c\u4ee5\u963b\u65b7\u764c\u7d30\u80de\u7684\u751f\u9577\u6216\u9a45\u4f7f\u5176\u81ea\u6211\u7834\u58de\u3002\u6a19\u9776\u6cbb\u7642\u8207\u5316\u5b78\u6cbb\u7642\u6700\u5927\u7684\u5dee\u7570\u662f\uff0c\u6a19\u9776\u85e5\u7269\u50c5\u5f71\u97ff\u5e36\u7279\u5b9a\u6a19\u7684\u764c\u7d30\u80de\uff0c\u800c\u4e0d\u6703\u5e72\u64fe\u6b63\u5e38\u7d30\u80de\uff0c\u56e0\u6b64\u901a\u5e38\u4e5f\u6709\u8f03\u4f4e\u7684\u526f\u4f5c\u7528\u767c\u751f\u3002<\/span><\/p>\n<\/div>\n

\n

\u2022 \u514d\u75ab\u6cbb\u7642:<\/strong><\/span><\/p>\n<\/div>\n

\n

\u7406\u8ad6\u4e0a\u4f86\u8aaa\uff0c\u764c\u7d30\u80de\u901a\u5e38\u5e36\u6709\u8207\u6b63\u5e38\u7d30\u80de\u4e0d\u540c\u7684\u5206\u5b50\uff0c\u56e0\u6b64\u53ef\u88ab\u514d\u75ab\u7cfb\u7d71\u8996\u70ba\u5916\u4f86\u7269\u800c\u653b\u64ca\uff0c\u4f46\u764c\u7d30\u80de\u6703\u900f\u904e\u57fa\u56e0\u8b8a\u7570\u3001\u91cb\u653e\u8a0a\u865f\u6216\u6539\u8b8a\u5468\u570d\u74b0\u5883\u7b49\u65b9\u5f0f\uff0c\u4f7f\u5f97\u514d\u75ab\u7cfb\u7d71\u4e0d\u5c0d\u5176\u6d3b\u5316\uff0c\u800c\u9003\u812b\u653b\u64ca\u3002\u514d\u75ab\u6cbb\u7642\u5373\u70ba\u900f\u904e\u4e00\u7a2e\u540d\u70ba\u300c\u514d\u75ab\u6aa2\u67e5\u6291\u5236\u5291 (Immune checkpoint blockade)\u300d\u7684\u85e5\u7269\uff0c\u963b\u65b7\u764c\u7d30\u80de\u7684\u300c\u514d\u75ab\u9003\u812b\u300d\u8a0a\u865f\uff0c\u800c\u80fd\u91cd\u65b0\u88ab\u514d\u75ab\u7cfb\u7d71\u6240\u8b58\u5225\u8207\u653b\u64ca\u3002<\/span><\/p>\n<\/div>\n

\n

\u6a19\u9776\u85e5\u7269\u4f7f\u764c\u75c7\u6cbb\u7642\u300c\u7cbe\u6e96\u5316\u300d<\/strong><\/span><\/h2>\n<\/div>\n
\n

\u8fd1\u5e7e\u5341\u5e74\u4f86\uff0c\u5df2\u6709\u8a31\u591a\u7814\u7a76\u8b49\u5be6\u764c\u75c7\u767c\u751f\u662f\u6e90\u81ea\u65bc\u300c\u57fa\u56e0\u8b8a\u7570\u300d\uff0c\u7576\u8b8a\u7570\u5728\u7d30\u80de\u4e2d\u4e0d\u65b7\u88ab\u7d2f\u7a4d\u4e14\u7121\u6cd5\u4fee\u5fa9\u6642\uff0c\u5c31\u53ef\u80fd\u5c0e\u81f4\u6b63\u5e38\u7d30\u80de\u8f49\u5316\u70ba\u764c\u7d30\u80de\u3002\u56e0\u6b64\uff0c\u82e5\u80fd\u76f4\u63a5\u91dd\u5c0d\u9020\u6210\u7d30\u80de\u764c\u5316\u7684\u57fa\u56e0\u8b8a\u7570\u9032\u884c\u300c\u6a19\u9776\u300d\u6cbb\u7642\u6642\uff0c\u4fbf\u6709\u6a5f\u6703\u63d0\u5347\u6cbb\u7642\u7684\u6210\u529f\u7387\u3002\u5982\u4e0a\u6240\u8ff0\uff0c\u6a19\u9776\u85e5\u7269\u53ef\u91dd\u5c0d\u7279\u5b9a\u7684\u57fa\u56e0\u8b8a\u7570\uff0c\u8996\u57fa\u56e0\u7279\u6027\u7684\u4e0d\u540c\uff0c\u963b\u65b7\u6216\u6d3b\u5316\u57fa\u56e0\u529f\u80fd\uff0c\u4ee5\u6291\u5236\u764c\u7d30\u80de\u751f\u9577\uff0c\u8209\u4f8b\u4f86\u8aaa\uff0c\u53f0\u7063\u70ba\u9ad8\u5ea6\u80ba\u817a\u764c\u767c\u751f\u7387\u7684\u570b\u5bb6\uff0c\u5176\u4e2d\u60a3\u8005\u5e36\u6709\u7684\u9a45\u52d5\u57fa\u56e0\u8b8a\u7570\u983b\u7387\u8207\u76f8\u95dc\u6a19\u9776\u85e5\u7269\u6709\uff1a<\/span><\/p>\n<\/div>\n

<\/div>\n
\n
\n
\n
\n\n\n\n\n<\/colgroup>\n\n\n\n\n\n\n\n\n\n
\n
\n

\u57fa\u56e0<\/strong><\/span><\/p>\n<\/div>\n

<\/div>\n
<\/div>\n
<\/div>\n
<\/div>\n<\/td>\n
\n
\n

\u8b8a\u7570\u983b\u7387<\/strong><\/span><\/p>\n<\/div>\n

<\/div>\n
<\/div>\n
<\/div>\n
<\/div>\n<\/td>\n
\n
\n

\u6a19\u9776\u85e5\u7269<\/strong><\/span><\/p>\n<\/div>\n

<\/div>\n
<\/div>\n
<\/div>\n
<\/div>\n<\/td>\n<\/tr>\n
\n
\n

EGFR<\/span><\/p>\n

(\u8868\u76ae\u751f\u9577\u56e0\u5b50\u53d7\u9ad4, epidermal growth factor receptor)<\/span><\/p>\n<\/div>\n

<\/div>\n
<\/div>\n
<\/div>\n
<\/div>\n<\/td>\n
\n
\n

55%<\/span><\/p>\n<\/div>\n

<\/div>\n
<\/div>\n
<\/div>\n
<\/div>\n<\/td>\n
\n
\n

Gefitinib (\u611b\u745e\u838e, Iressa)<\/span><\/p>\n

Erlotinib (\u5f97\u8212\u7de9, Tarceva)<\/span><\/p>\n

Afatinib (\u59a5\u5fa9\u514b, Gilotrif)<\/span><\/p>\n

Osimertinib (\u6cf0\u683c\u838e, Tagrisso)<\/span><\/p>\n<\/div>\n

<\/div>\n
<\/div>\n
<\/div>\n
<\/div>\n<\/td>\n<\/tr>\n
\n
\n

ALK<\/span><\/p>\n

(\u9593\u8b8a\u6027\u6dcb\u5df4\u7624\u6fc0\u9176, anaplastic lymphoma kinase)<\/span><\/p>\n<\/div>\n

<\/div>\n
<\/div>\n
<\/div>\n
<\/div>\n<\/td>\n
\n
\n

5%<\/span><\/p>\n<\/div>\n

<\/div>\n
<\/div>\n
<\/div>\n
<\/div>\n<\/td>\n
\n
\n

Crizotinib (\u622a\u524b\u7624, Xakori)<\/span><\/p>\n

Ceritinib (\u7acb\u514b\u764c, Zykadia)<\/span><\/p>\n

Alectinib (\u5b89\u7acb\u9069, Alecensa)<\/span><\/p>\n<\/div>\n

<\/div>\n
<\/div>\n
<\/div>\n
<\/div>\n<\/td>\n<\/tr>\n
\n
\n

KRAS<\/span><\/p>\n

(Kirsten\u5927\u9f20\u8089\u76242\u75c5\u6bd2\u81f4\u764c\u57fa\u56e0\u540c\u6e90\u9ad4, Kirsten rat sarcoma 2 viral oncogene homolog)<\/span><\/p>\n<\/div>\n

<\/div>\n
<\/div>\n
<\/div>\n
<\/div>\n<\/td>\n
\n
\n

5%<\/span><\/p>\n<\/div>\n

<\/div>\n
<\/div>\n
<\/div>\n
<\/div>\n<\/td>\n
\n
\n

\u7121<\/span><\/p>\n<\/div>\n

<\/div>\n
<\/div>\n
<\/div>\n
<\/div>\n<\/td>\n<\/tr>\n
\n
\n

MET<\/span><\/p>\n

(\u809d\u7d30\u80de\u751f\u9577\u56e0\u5b50\u53d7\u9ad4\u916a\u6c28\u9178\u6fc0\u9176, MET tyrosine kinase receptor)<\/span><\/p>\n<\/div>\n

<\/div>\n
<\/div>\n
<\/div>\n
<\/div>\n<\/td>\n
\n
\n

2-3%<\/span><\/p>\n<\/div>\n

<\/div>\n
<\/div>\n
<\/div>\n
<\/div>\n<\/td>\n
\n
\n

Tepotinib (\u5fb7\u9081\u7279, Tepmetko)<\/span><\/p>\n<\/div>\n

<\/div>\n
<\/div>\n
<\/div>\n
<\/div>\n<\/td>\n<\/tr>\n
\n
\n

ROS-1<\/span><\/p>\n

(\u8de8\u819c\u53d7\u9ad4\u86cb\u767d\u916a\u6c28\u9178\u6fc0\u9176, ROS tyrosine kinase receptor)<\/span><\/p>\n<\/div>\n

<\/div>\n
<\/div>\n
<\/div>\n
<\/div>\n<\/td>\n
\n
\n

1-2%<\/span><\/p>\n<\/div>\n

<\/div>\n
<\/div>\n
<\/div>\n
<\/div>\n<\/td>\n
\n
\n

Crizotinib (\u622a\u524b\u7624, Xakori)<\/span><\/p>\n<\/div>\n

<\/div>\n
<\/div>\n
<\/div>\n
<\/div>\n<\/td>\n<\/tr>\n
\n
\n

BRAF<\/span><\/p>\n

(\u7d72\u80fa\u9178-\u8607\u80fa\u9178\u86cb\u767d\u6fc0\u9176, B-Raf serine\/threonine kinase receptor)<\/span><\/p>\n<\/div>\n

<\/div>\n
<\/div>\n
<\/div>\n
<\/div>\n<\/td>\n
\n
\n

<1%<\/span><\/p>\n<\/div>\n

<\/div>\n
<\/div>\n
<\/div>\n
<\/div>\n<\/td>\n
\n
\n

Dabrafenib (\u6cf0\u4f0f\u6a02, Tafinlar)<\/span><\/p>\n

Trametinib (\u9ea5\u6b23\u9713, Mekinist)<\/span><\/p>\n<\/div>\n

<\/div>\n
<\/div>\n
<\/div>\n
<\/div>\n<\/td>\n<\/tr>\n
\n
\n

NTRK<\/span><\/p>\n

(\u795e\u7d93\u71df\u990a\u6027\u539f\u808c\u7403\u86cb\u767d\u53d7\u9ad4\u6fc0\u9176, neurotrophic tyrosine kinase receptor)<\/span><\/p>\n<\/div>\n

<\/div>\n
<\/div>\n
<\/div>\n
<\/div>\n<\/td>\n
\n
\n

<1%<\/span><\/p>\n<\/div>\n

<\/div>\n
<\/div>\n
<\/div>\n
<\/div>\n<\/td>\n
\n
\n

Entrectinib (\u7f85\u601d\u514b, Rozlytrek)<\/span><\/p>\n<\/div>\n

<\/div>\n
<\/div>\n
<\/div>\n
<\/div>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n
<\/div>\n
\n

*\u672c\u8868\u50c5\u5217\u51fa\u73fe\u80ba\u817a\u764c\u8f03\u5e38\u898b\u7684\u57fa\u56e0\u8207\u5176\u53f0\u7063\u6838\u51c6\u4e4b\u85e5\u7269\u3002<\/span><\/p>\n<\/div>\n

\n

\u57fa\u56e0\u8b8a\u7570\u9664\u5728\u4e0d\u540c\u764c\u7a2e\u9593\u5b58\u5728\u5dee\u7570\u4e4b\u5916\uff0c\u5728\u540c\u4e00\u764c\u7a2e\u7684\u4e0d\u540c\u60a3\u8005\u9593\u4e5f\u5b58\u5728\u4e0d\u540c\u7684\u8b8a\u7570\u5716\u8b5c\uff0c\u5982\u4e0a\u8ff0\u7684\u80ba\u817a\u764c\u7b49\uff1b\u751a\u81f3\u540c\u4e00\u764c\u7a2e\u5728\u4e0d\u540c\u7a2e\u65cf\u9593\u7684\u6574\u9ad4\u8b8a\u7570\u72c0\u6cc1\u4e5f\u4e0d\u540c\uff0c\u5982EGFR\u8b8a\u7570\u5728\u6771\u65b9\u80ba\u817a\u764c\u60a3\u8005\u4e2d\uff0c\u8b8a\u7570\u983b\u7387\u6700\u9ad8\uff0c\u4f46\u5728\u897f\u65b9\u80ba\u817a\u764c\u60a3\u8005\u4e2d\uff0c\u5247\u4ee5KRAS\u8b8a\u7570\u70ba\u4e3b\uff0c\u56e0\u6b64\u5728\u5927\u65b9\u5411\u7684\u6a19\u9776\u6cbb\u7642\u898f\u5283\u4e0a\uff0c\u4e5f\u9700\u8981\u300c\u91cf\u8eab\u5b9a\u505a\u300d\u3002<\/span><\/p>\n<\/div>\n

\n

\u764c\u75c7\u6cbb\u7642\u65b0\u91cc\u7a0b\u7891: \u300c\u514d\u75ab\u6cbb\u7642\u300d<\/strong><\/span><\/h2>\n<\/div>\n
\n

\u4e00\u822c\u4f86\u8aaa\uff0c\u7576\u4eba\u9ad4\u88ab\u7d30\u83cc\u3001\u75c5\u6bd2\u6216\u764c\u7d30\u80de\u7b49\u6240\u4fb5\u5165\u6642\uff0c\u514d\u75ab\u7cfb\u7d71\u4fbf\u6703\u555f\u52d5\uff0c\u4ee5\u9664\u53bb\u9019\u4e9b\u5916\u4f86\u7269\u8cea\uff0c\u4f46\u70ba\u4f55\u764c\u7d30\u80de\u80fd\u7121\u6b62\u76e1\u7684\u767c\u80b2\u9577\u5927\uff0c\u751a\u81f3\u8f49\u79fb\u81f3\u8eab\u9ad4\u5404\u90e8\u4f4d\uff0c\u5176\u4e2d\u9664\u4e86\u5176\u672c\u8eab\u7570\u5e38\u7684\u751f\u9577\u7279\u6027\u5916\uff0c\u53e6\u4e00\u500b\u95dc\u9375\u56e0\u7d20\u662f\u300c\u514d\u75ab\u6aa2\u67e5\u9ede\u300d\u3002\u6240\u8b02\u300c\u514d\u75ab\u6aa2\u67e5\u9ede\u300d\u662f\u4e00\u7a2e\u4fdd\u8b77\u6a5f\u5236\uff0c\u4e3b\u8981\u662f\u5728\u767c\u751f\u514d\u75ab\u53cd\u61c9\u6642\uff0c\u907f\u514d\u5176\u904e\u5ea6\u6fc0\u70c8\u800c\u50b7\u5bb3\u5230\u6b63\u5e38\u7d30\u80de\u6216\u7d44\u7e54\uff0c\u800c\u764c\u7d30\u80de\u4fbf\u662f\u900f\u904e\u904e\u5ea6\u6d3b\u5316\u514d\u75ab\u6aa2\u67e5\u9ede\uff0c\u4f86\u507d\u88dd\u6210\u6b63\u5e38\u7d30\u80de\uff0c\u907f\u958b\u514d\u75ab\u7cfb\u7d71\u653b\u64ca\u3002\u56e0\u6b64\uff0c\u514d\u75ab\u6cbb\u7642\u5c31\u662f\u7528\u85e5\u7269\u4f86\u963b\u65b7\u764c\u7d30\u80de\u7684\u514d\u75ab\u6aa2\u67e5\u9ede\uff0c\u6216\u662f\u589e\u52a0\u514d\u75ab\u7d30\u80de\u7684\u6d3b\u6027\u8207\u6578\u91cf\uff0c\u91cd\u65b0\u6fc0\u6d3b\u514d\u75ab\u7cfb\u7d71\u5c0d\u764c\u7d30\u80de\u7522\u751f\u4f5c\u7528\u3002<\/span><\/p>\n<\/div>\n

\n

\u76ee\u524d\u6700\u5e38\u898b\u7684\u514d\u75ab\u6cbb\u7642\u662f\u300c\u514d\u75ab\u6aa2\u67e5\u9ede\u6291\u5236\u5291\u300d\u6cbb\u7642\uff0c\u5728\u53f0\u7063\u5df2\u6709\u5206\u5225\u91dd\u5c0dCTLA-4 (\u7d30\u80de\u6bd2\u6027T\u6dcb\u5df4\u7d30\u80de\u76f8\u95dc\u6297\u539f4, cytotoxic T-lymphocyte-associated protein 4) \u8207PD-1\/PD-L1 (\u7a0b\u5e8f\u5316\u6b7b\u4ea1\u86cb\u767d1\/\u7a0b\u5e8f\u5316\u6b7b\u4ea1-\u914d\u9ad41, programmed cell death protein 1\/programmed cell death-Ligand 1) \u9019\u5169\u500b\u514d\u75ab\u6aa2\u67e5\u9ede\u7684\u56db\u7a2e\u514d\u75ab\u6cbb\u7642\u85e5\u7269\uff0c\u5206\u5225\u662f:<\/span><\/p>\n<\/div>\n

\n

\u2022 Ipilimumab (\u76ca\u4f0f, Yervoy, anti-CTLA-4)\uff0c<\/span><\/p>\n<\/div>\n

\n

\u2022 Nivolumab (\u4fdd\u75be\u4f0f, Opdivo, anti-PD-1)\uff0c<\/span><\/p>\n<\/div>\n

\n

\u2022 Pembrolizumab (\u5409\u8212\u9054, Keytruda, anti-PD-1)\uff0c<\/span><\/p>\n<\/div>\n

\n

\u2022 Atezolizumab (\u764c\u81ea\u79a6, Tecentriq, anti-PD-L1)\uff0c<\/span><\/p>\n<\/div>\n

\n

\u9019\u4e9b\u85e5\u7269\u5728\u9ed1\u8272\u7d20\u7624\u3001\u80ba\u764c\u3001\u6ccc\u5c3f\u4e0a\u76ae\u764c\u3001\u80c3\u764c\u3001\u5927\u8178\u76f4\u8178\u764c\u8207\u982d\u9838\u764c\u7b49\u7686\u80fd\u6709\u6548\u63d0\u5347\u4e94\u5e74\u5b58\u6d3b\u7387\u8207\u4e94\u5e74\u7121\u60e1\u5316\u5b58\u6d3b\u7387\u3002\u4f46\u9019\u4e9b\u85e5\u7269\u4e5f\u4e26\u975e\u5c0d\u6240\u6709\u60a3\u8005\u7686\u6709\u6548\uff0c\u5982\u679c\u764c\u7d30\u80de\u4e0d\u5177\u6709\u4e0b\u5217\u7279\u5fb5\u6642\uff0c\u5982 (1) \u514d\u75ab\u6aa2\u67e5\u9ede\u7684\u9ad8\u8868\u73fe\u91cf\u3001(2) \u57fa\u56e0\u5177\u9ad8\u5ea6\u5fae\u885b\u661f\u9ad4\u4e0d\u7a69\u5b9a\u6027 (Microsatellite instability) \u8207 (3) \u9ad8\u5ea6\u7a81\u8b8a\u91cf\u7b49\uff0c\u53ef\u80fd\u7642\u6548\u4e5f\u6703\u5f88\u6709\u9650\u3002\u56e0\u6b64\uff0c\u5728\u9032\u884c\u6cbb\u7642\u524d\uff0c\u9084\u662f\u9700\u8981\u7d9c\u5408\u8a55\u4f30\u6cbb\u7642\u53ef\u884c\u6027\uff0c\u4ee5\u53ca\u8a72\u5982\u4f55\u642d\u914d\u4e0d\u540c\u7684\u6cbb\u7642\u7b56\u7565\uff0c\u4ee5\u6c42\u771f\u6b63\u6709\u6548\u7684\u6cbb\u7642\u3002<\/span><\/p>\n<\/div>\n

\n

\u672c\u7bc7\u6211\u5011\u4e86\u89e3\u5230\u57fa\u56e0\u5982\u4f55\u53c3\u8207\u764c\u75c7\u6cbb\u7642\uff0c\u4e26\u4f7f\u6574\u9ad4\u6cbb\u7642\u7cbe\u6e96\u5316\u3002\u4e0b\u4e00\u7bc7\u6211\u5011\u5c07\u7c21\u4ecb\u57fa\u56e0\u6578\u64da\u5982\u4f55\u8ddf\u73fe\u5728\u5341\u5206\u71b1\u9580\u7684\u4eba\u5de5\u667a\u6167\u4f5c\u7d50\u5408\uff0c\u4e26\u61c9\u7528\u65bc\u672a\u4f86\u7684\u764c\u75c7\u6cbb\u7642\u4e2d\u3002<\/span><\/p>\n<\/div>\n

\n

\u82e5\u6b32\u9032\u4e00\u6b65\u4e86\u89e3\u66f4\u591a\u8cc7\u8a0a\uff0c\u6b61\u8fce\u5bc4\u4fe1\u81f3Bryant.chen@be.tworg.app<\/span><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

\u4e0a\u4e00\u7bc7\u6211\u5011\u7c21\u55ae\u8aaa\u660e\u4e86\u57fa\u56e0\u8207\u764c\u75c7\u53ca\u5169\u8005\u9593\u7684\u95dc\u806f\u6027\uff0c\u9019\u4e00\u7bc7\u6211\u5011\u4f86\u804a\u804a\u904e\u5f80\u6709\u54ea\u4e9b\u764c\u75c7\u6cbb\u7642\u65b9\u5f0f\uff0c\u4ee5\u53ca\u76ee\u524d\u57fa\u56e0\u6578\u64da\u662f\u5982\u4f55 […]<\/p>\n","protected":false},"author":1,"featured_media":6878,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[34],"tags":[],"class_list":["post-7454","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-article"],"acf":[],"_links":{"self":[{"href":"https:\/\/behealthventures.com\/zh-hant\/wp-json\/wp\/v2\/posts\/7454","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/behealthventures.com\/zh-hant\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/behealthventures.com\/zh-hant\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/behealthventures.com\/zh-hant\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/behealthventures.com\/zh-hant\/wp-json\/wp\/v2\/comments?post=7454"}],"version-history":[{"count":1,"href":"https:\/\/behealthventures.com\/zh-hant\/wp-json\/wp\/v2\/posts\/7454\/revisions"}],"predecessor-version":[{"id":7456,"href":"https:\/\/behealthventures.com\/zh-hant\/wp-json\/wp\/v2\/posts\/7454\/revisions\/7456"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/behealthventures.com\/zh-hant\/wp-json\/wp\/v2\/media\/6878"}],"wp:attachment":[{"href":"https:\/\/behealthventures.com\/zh-hant\/wp-json\/wp\/v2\/media?parent=7454"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/behealthventures.com\/zh-hant\/wp-json\/wp\/v2\/categories?post=7454"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/behealthventures.com\/zh-hant\/wp-json\/wp\/v2\/tags?post=7454"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}